Purple Biotech Stock Debt To Equity
| PPBT Stock | ILA 4.80 0.20 4.00% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
Purple |
Purple Biotech Company Debt To Equity Analysis
Purple Biotech's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Purple Biotech Debt To Equity | 0.01 % |
Most of Purple Biotech's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Purple Biotech has a Debt To Equity of 0.011%. This is 99.98% lower than that of the Healthcare sector and 99.94% lower than that of the Biotechnology industry. The debt to equity for all Israel stocks is 99.98% higher than that of the company.
Purple Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is rated below average in debt to equity category among its peers.
Purple Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (5 M) | |||
| Shares Outstanding | 205.98 M | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 56.01 X | |||
| Gross Profit | (55 K) | |||
| EBITDA | (21.43 M) | |||
| Net Income | (21.67 M) | |||
| Cash And Equivalents | 48.39 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 804 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 14.30 X | |||
| Book Value Per Share | 0.26 X | |||
| Cash Flow From Operations | (16.73 M) | |||
| Earnings Per Share | (0.11) X | |||
| Beta | 1.51 | |||
| Market Capitalization | 134.51 M | |||
| Total Asset | 54.62 M | |||
| Net Asset | 54.62 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.